skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon


actionable intelligence pharma intelligence



  • ディール、提携、買収、ベンチャー企業の資金調達に関する情報
  • 医薬品とディールトレンドのベンチマーキング
  • 医薬品パイプラインのトラッキングと評価
  • 特許とジェネリック
  • 臨床試験と薬事に関するイベント
  • 医薬品承認確率と諮問委員会の見解
  • DDS
  • 競合状況の調査




HBW Insight : コンシューマーヘルスケア産業のニュース

HBW Insightでは、市販薬(OTC)、ビタミンなどのサプリメント(栄養補助食品)、化粧品、衛生用品やスキンケアなどコンシューマーヘルスケア産業のニュースをワンストップでお届けします。ビジネスの動向だけでなく、規制や法律に関しても専門アナリストの分析と見解を交えてお伝えします。今後ますますグローバル化する業界の機会とリスクを予測するのに役立ちます。

Key benefits:

  • 世界のコンシューマー ヘルスケア産業を把握
  • 市場の最新ニュースと 予測を誰よりもはやく
  • 国際競争力を強化する独自のニュースと分析


A web-based analytics tool with optional consulting services, Pharmapremia provides robust and unbiased success rate and timeline metrics.

Key benefits:

  • Manage portfolio risks
  • 成功要因の分析
  • Create meaningful benchmarks

Scrip: 世界の医療用医薬品&製薬産業に関するニュース


Key benefits:

  • ジャーナリストによる世界の医薬品市場動向
  • 国際競争力を強化する独自のニュースと分析
  • 製薬業界の<br>最前線が分かる


  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Get your FREE extract of the 2021 Scrip Asia 100 Report Now | Pharma Intelligence

    17 Jun 2022

    Get your FREE extract of the 2021 Scrip Asia 100 Report Now | Pharma Intelligence

    As we continue to navigate unprecedented times, the pharma industry in the Asia Pacific region has been persistently moving forward with clinical trial advancements.

    Topic Business Strategies

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Scrip Titans of Pharma

    16 Jun 2022

    Scrip Titans of Pharma

    The 2021 Titans of Pharma provides snapshot of the industry’s top 15 leaders and the businesses they oversee, with vital statistics covering the compensation of CEOs and R&D heads, median employee pay, and company performance. 

    Topic Business Strategies Leadership

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Coronavirus Update: Korea Approval For Nuvaxovid, Japan Filing For Paxlovid

    By Scrip Team 18 Jan 2022


    More progress for vaccines and oral antivirals in Asia as South Korea issues an approval for Novavax's vaccine, Pfizer files for Japanese approval of Paxlovid, and SK bio progresses late-stage trials of its recombinant vaccine. 

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?

    By Joseph Haas 17 Jan 2022


    Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip's Five Must-Know Things

    By Ian Haydock 17 Jan 2022


    In this week's podcast edition of Five Must-Know Things: easy alliances rather than big deals the focus at JP Morgan; multiple company roundups from JPM; and Lilly braces for impact of US CMS decision on Aduhelm.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    A Deep Dive Into The Game-Changing Drugs For Skin Diseases

    By Scrip Team 17 Jan 2022


    Scrip's Kevin Grogan joins Datamonitor's Pamela Spicer and Davinderpreet Mangat to discuss the skin disease landscape and whether atopic dermatitis is now where psoriasis was a decade ago as another wave of innovative products start to reach the market.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    US FDA Says White Paper Could Inform Rulemaking For Cosmetic Talc-Asbestos Testing

    By Ryan Nelson 14 Jan 2022


    Formed by the FDA in fall 2018 and convened in early 2020 for a public meeting, the Interagency Working Group on Asbestos in Consumer Products maintains that electron microscopy should be a first-line method for detecting asbestos in cosmetic talc and talc-containing products, and that labs should report elongate mineral particles beyond those classically understood as asbestos.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Gilead Aims For Oncology To Provide One-Third Of Revenues By 2030

    By Alaric DeArment 10 Jan 2022


    At the J.P. Morgan meeting, the company said its business development priorities have not changed, but it plans to prioritize licensing and small acquisitions rather than big ticket deals in 2022.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Quick Listen: Scrip's Five Must-Know Things

    By Ian Haydock 10 Jan 2022


    In this week's podcast edition of Five Must-Know Things: new mRNA vaccine deal for Pfizer and BioNTech; court ruling helps Novartis’s Gilenya; first cut-price generic Paxlovid launched; breaking down BridgeBio’s Phase III failure; and a look at gene editing companies to watch at JP Morgan.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    BioNTech Deal Shows Pfizer Is Reinvesting COVID-19 Windfall In mRNA

    By Alaric DeArment 05 Jan 2022


    The companies’ third vaccine-development deal shows how COVID cash has also led mRNA-focused companies to beef up their organic pipelines amid talk of a merger wave.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Five (Non-COVID) Clinical Trial Misses Of 2021

    By Alex Shimmings 04 Jan 2022


    The coronavirus pandemic may have dominated the news in 2021, but industry’s more bread and butter R&D activities continued. Here, Scrip takes a look at five of the more notable clinical trial misses of the year that got readers clicking.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    MIG Capital: BioNTech Has Transformed Global View Of German Biotech 'But We Don’t Walk On Water’

    By Andrew McConaghie 23 Dec 2021


    MIG Capital’s Matthias Kromayer looks back at the huge success of its long-term backing of BioNTech and discusses the group’s next big life sciences investments, but warns that realism and hard work are needed to achieve another breakthrough.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Ocugen CEO Musunuri On Gene Therapy Candidates, The Omicron Advantage

    By Vibha Ravi 22 Dec 2021


    Ocugen’s mutation-agnostic candidate for retinitis pigmentosa and leber congenital amaurosis is set for Phase I trials in the US. In this exclusive audio interview, founder and CEO Shankar Musunuri speaks to Scrip about seeking partners beyond CanSino Biologics for the candidate while stressing Bharat Biotech’s COVID-19 vaccine could hold promise against the Omicron variant.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    APAC Podcast: Policies Play Out Against Pandemic, Corporate Activity Remains Strong

    By Ian Haydock 01 Dec 2021


    Join the Asia Pacific content team for a wide-ranging overview and analysis of recent developments across China, India, South Korea and Japan in the policy, regulatory, commercial and vaccines spaces over the past few months. 

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    COVID-19 Vaccine Makers Pledge Rapid Response To Omicron Threat

    By Andrew McConaghie 29 Nov 2021


    While news of a potentially highly transmissible new variant is causing alarm, Pfizer/BioNTech and Moderna are already pursuing a multi-pronged response to B.1.1.529.